Processa Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 13
- Market Cap
- -
- Introduction
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on...
A Phase 2 Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT06568692
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT05270460
- Locations
- 🇺🇸
Long Island Gastrointestinal Research Group, Great Neck, New York, United States
🇺🇸APF Research, LLC, Miami, Florida, United States
🇺🇸Torrance Clinical Research Institute, Inc., Lomita, California, United States
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT04861987
- Locations
- 🇺🇸
Processa Clinical Site, Fairfax, Virginia, United States
A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04800562
- Locations
- 🇺🇸
Processa Clinical Site, Milwaukee, Wisconsin, United States
Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03836222
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT03698864
- Locations
- 🇺🇸
Processa Investigational Site, Pittsburgh, Pennsylvania, United States
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT03189914
- Locations
- 🇺🇸
Rexahn Site, Milwaukee, Wisconsin, United States
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT02030067
- Locations
- 🇺🇸
Rexahn Site, Fairfax, Virginia, United States
Open Label Extension Study of HT-100 in Patients With DMD
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01978366
- Locations
- 🇺🇸
Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Processa Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01847573
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States